MX2018009952A - Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1. - Google Patents

Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1.

Info

Publication number
MX2018009952A
MX2018009952A MX2018009952A MX2018009952A MX2018009952A MX 2018009952 A MX2018009952 A MX 2018009952A MX 2018009952 A MX2018009952 A MX 2018009952A MX 2018009952 A MX2018009952 A MX 2018009952A MX 2018009952 A MX2018009952 A MX 2018009952A
Authority
MX
Mexico
Prior art keywords
acetylcholine receptor
positive allosteric
allosteric modulators
muscarinic acetylcholine
compounds
Prior art date
Application number
MX2018009952A
Other languages
English (en)
Inventor
Jeffrey Conn P
W Lindsley Craig
W Engers Darren
A Bollinger Katrina
L Engers Julie
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MX2018009952A publication Critical patent/MX2018009952A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen moduladores alostéricos positivos del receptor de acetilcolina muscarínico M1 (mAChR M1), composiciones farmacéuticas que incluyen los compuestos, y métodos para usar los compuestos y composiciones para tratar trastornos neurológicos, trastornos psiquiátricos o una combinación de los mismos.
MX2018009952A 2016-02-16 2017-02-16 Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1. MX2018009952A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296012P 2016-02-16 2016-02-16
US201662402438P 2016-09-30 2016-09-30
PCT/US2017/018140 WO2017143041A1 (en) 2016-02-16 2017-02-16 Positive allosteric modulators of the muscarinic acetylcholine receptor m1

Publications (1)

Publication Number Publication Date
MX2018009952A true MX2018009952A (es) 2018-11-29

Family

ID=59626207

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009952A MX2018009952A (es) 2016-02-16 2017-02-16 Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1.

Country Status (15)

Country Link
US (1) US11111251B2 (es)
EP (1) EP3416639B1 (es)
JP (1) JP2019504901A (es)
KR (1) KR20180110132A (es)
CN (1) CN109069491A (es)
AU (1) AU2017221404A1 (es)
BR (1) BR112018016689A2 (es)
CA (1) CA3014791A1 (es)
CL (1) CL2018002335A1 (es)
EA (1) EA201891854A1 (es)
IL (1) IL261058A (es)
MA (1) MA44253A (es)
MX (1) MX2018009952A (es)
PH (1) PH12018501731A1 (es)
WO (1) WO2017143041A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2824495T3 (es) * 2016-09-02 2021-05-12 Suven Life Sciences Ltd Moduladores alostéricos positivos del receptor muscarínico M1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
PT3643718T (pt) * 2017-06-20 2023-10-26 Takeda Pharmaceuticals Co Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
CN110709401B (zh) * 2017-06-20 2023-06-13 武田药品工业株式会社 杂环化合物
CN118063442A (zh) 2017-10-20 2024-05-24 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
BR112020008050A2 (pt) * 2017-10-27 2020-11-03 Suven Life Sciences Limited composto modulador alostérico positivo de receptor muscarínico m1, composição farmacêutica compreendendo o referido composto, uso dos mesmos e combinação
WO2019089676A1 (en) 2017-10-31 2019-05-09 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
EP3746421B1 (en) 2018-02-02 2023-11-29 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US11851406B2 (en) * 2018-06-13 2023-12-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2020067456A1 (ja) 2018-09-28 2020-04-02 武田薬品工業株式会社 複素環化合物
EP3858823A4 (en) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC COMPOUND
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
EP4037677A4 (en) * 2019-10-04 2023-05-03 Vanderbilt University MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ANTAGONISTS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608079A (en) 1983-08-02 1986-08-26 American Cyanamid Company Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU759875B2 (en) 1999-03-09 2003-05-01 Pharmacia & Upjohn Company 4-OXO-4,7-dihydro-thieno(2,3-b)pyridine-5-carboxamides as antiviral agents
CA2407594A1 (en) 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists
DK1432707T3 (da) * 2001-10-02 2012-06-11 Pharmacia & Upjohn Co Llc Azabicyklisk-substituerede kondenserede heteroarylforbindelser til behandling af sygdomme
PL2512243T3 (pl) * 2009-12-17 2016-09-30 Pozytywne modulatory allosteryczne receptora amidu chinoliny m1
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
US8940765B2 (en) 2011-05-17 2015-01-27 Merck Sharp & Dohme Corp. N-linked quinolineamide M1 receptor positive allosteric modulators
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CA2930961A1 (en) 2014-01-22 2015-07-30 F. Hoffmann-La Roche Ag Fluoro-naphthyl derivatives
JP6571077B2 (ja) * 2014-06-13 2019-09-04 武田薬品工業株式会社 含窒素複素環化合物
WO2016009297A1 (en) * 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016029454A1 (en) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
ES2824495T3 (es) 2016-09-02 2021-05-12 Suven Life Sciences Ltd Moduladores alostéricos positivos del receptor muscarínico M1

Also Published As

Publication number Publication date
US11111251B2 (en) 2021-09-07
EP3416639B1 (en) 2022-06-08
PH12018501731A1 (en) 2019-06-17
WO2017143041A1 (en) 2017-08-24
CL2018002335A1 (es) 2019-02-01
EA201891854A1 (ru) 2019-01-31
US20210230180A1 (en) 2021-07-29
EP3416639A1 (en) 2018-12-26
CN109069491A (zh) 2018-12-21
AU2017221404A1 (en) 2018-08-23
CA3014791A1 (en) 2017-08-24
JP2019504901A (ja) 2019-02-21
EP3416639A4 (en) 2019-07-03
MA44253A (fr) 2018-12-26
KR20180110132A (ko) 2018-10-08
BR112018016689A2 (pt) 2019-02-12
IL261058A (en) 2018-10-31

Similar Documents

Publication Publication Date Title
PH12018501731A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
GEP20207167B (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
CL2016002661A1 (es) Compuestos derivados de isoindolin-1-ona, con actividad del receptor colinérgico muscarínico m1 del modulador alostérico positivo; composición farmacológica; útiles para el tratamiento del alzheimer, esquizofrenia, dolor, trastornos del sueño, demencia asociada al parkinson o demencia con cuerpos de lewy.
NZ737399A (en) Ccr2 modulators
CL2018002697A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos.
PH12016500529A1 (en) 4-azaindole derivatives
PH12019501079A1 (en) Magl inhibitors
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
PH12019500196A1 (en) Compounds and compositions and uses thereof
BR112018016629A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
EP3558307A4 (en) 6,6-FUSED HETERARYARYL PIPERIDINE ETHER MODULATORS OF ACETYLCHOLINE MUSCARINIC M4 RECEPTOR
ZA202001321B (en) Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3534901A4 (en) POSITIVE ALLOSTERIC MODULATORS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
EP3544961A4 (en) POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINE ACETYLCHOLINE RECEPTOR M4
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
RS64722B1 (sr) Heterociklično jedinjenje i njegova upotreba kao pozitivnog alosteričkog modulatora holinergičkog muskarinskog m1 receptora
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
BR112018007755A2 (pt) moduladores alostéricos positivos do receptor muscarínico m4 de acetilcolina
PL3586832T3 (pl) Kompozycja farmaceutyczna do leczenia zaparcia
EP3424506A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNCTIONAL PSYCHIATRIC DISORDER
BR112017014226A2 (pt) derivados de heterociclilalquina e sua utilização como moduladores de receptores mglur5